ストックスクリーナーアプリを入手
33.73
4.23%
1.37
前日終値:
$32.36
開ける：
$32.57
24時間の取引高:
229.76K
Relative Volume:
0.59
時価総額：
$1.71B
収益：
$379.74M
当期純損益:
$-29.11M
株価収益率:
-57.73
EPS:
-0.5843
ネットキャッシュフロー:
$2.86M
1週間 パフォーマンス:
+4.88%
1か月 パフォーマンス:
+7.08%
6か月 パフォーマンス:
-4.34%
1年 パフォーマンス:
+15.32%
1日の値動き範囲:
$32.19
$33.86
1週間の範囲:
$30.52
$33.86
52週間の値動き範囲:
$23.15
$40.71
Immunocore Holdings Plc Adr Stock (IMCR) Company Profile
名前
Immunocore Holdings Plc Adr
セクター
電話
01235 5430281
住所
90 PARK DRIVE, OXFORDSHIRE
Compare IMCR vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IMCR
Immunocore Holdings Plc Adr
|
33.73 | 1.64B | 379.74M | -29.11M | 2.86M | -0.5843 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immunocore Holdings Plc Adr Stock (IMCR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-07 | アップグレード | UBS | Sell → Buy |
| 2025-10-31 | 開始されました | Wells Fargo | Overweight |
| 2025-09-18 | 再開されました | Guggenheim | Neutral |
| 2025-08-25 | 再開されました | Jefferies | Buy |
| 2025-05-27 | 開始されました | Deutsche Bank | Buy |
| 2024-12-13 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-11-11 | ダウングレード | Mizuho | Outperform → Neutral |
| 2024-10-24 | 開始されました | UBS | Sell |
| 2024-10-07 | ダウングレード | Guggenheim | Buy → Neutral |
| 2024-04-29 | 開始されました | Leerink Partners | Outperform |
| 2023-11-20 | 再開されました | JP Morgan | Overweight |
| 2023-11-02 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-10-31 | 開始されました | Robert W. Baird | Outperform |
| 2023-09-13 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-09-13 | 開始されました | Needham | Buy |
| 2023-08-16 | 開始されました | CapitalOne | Overweight |
| 2023-07-17 | 開始されました | Canaccord Genuity | Hold |
| 2023-03-31 | 開始されました | Mizuho | Buy |
| 2023-03-30 | 開始されました | Guggenheim | Buy |
| 2023-03-24 | 開始されました | Bryan Garnier | Buy |
| 2022-12-16 | アップグレード | Goldman | Neutral → Buy |
| 2022-11-30 | 開始されました | Barclays | Overweight |
| 2022-09-09 | 開始されました | Morgan Stanley | Overweight |
| 2022-09-08 | 開始されました | Ladenburg Thalmann | Buy |
| 2022-08-08 | 開始されました | Cowen | Outperform |
| 2022-08-02 | 開始されました | BTIG Research | Buy |
| 2022-02-08 | 開始されました | H.C. Wainwright | Buy |
| 2021-10-20 | 開始されました | Oppenheimer | Outperform |
| 2021-03-02 | 開始されました | Goldman | Neutral |
| 2021-03-02 | 開始されました | JP Morgan | Overweight |
| 2021-03-02 | 開始されました | Jefferies | Buy |
すべてを表示
Immunocore Holdings Plc Adr (IMCR) 最新ニュース
Immunocore to present at upcoming investor conferences - GlobeNewswire Inc.
Immunocore (NASDAQ:IMCR) Price Target Raised to $75.00 at Needham & Company LLC - Defense World
Immunocore Q4 Earnings Call Highlights - Yahoo Finance
Immunocore Holdings earnings missed by $0.40, revenue fell short of estimates - Investing.com South Africa
RXRX Q4 Loss Narrower Than Expected, Revenues Increase Y/Y, Stock Up - Finviz
JAZZ Stock Rises as Q4 Earnings & Sales Top Expectations - Finviz
Repligen's Q4 Earnings Beat Estimates, Revenues Surge Y/Y - Finviz
Apellis Q4 Loss Wider Than Expected, Revenues Decline Y/Y - Finviz
Earnings call transcript: Immunocore Holdings Q4 2025 reveals strong growth, stock dips By Investing.com - Investing.com South Africa
Earnings call transcript: Immunocore Holdings Q4 2025 reveals strong growth, stock dips - Investing.com India
Immunocore earnings ahead as melanoma pipeline advances - Investing.com India
Immunocore earnings ahead as melanoma pipeline advances By Investing.com - Investing.com South Africa
Madrigal Q4 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Down - Finviz
Immunocore (NASDAQ:IMCR) CAO John Goll Sells 698 Shares - MarketBeat
Leger Tina Amber St Sells 1,000 Shares of Immunocore (NASDAQ:IMCR) Stock - MarketBeat
Immunocore (NASDAQ:IMCR) CEO Bahija Jallal Sells 11,474 Shares - MarketBeat
David Berman Sells 5,965 Shares of Immunocore (NASDAQ:IMCR) Stock - MarketBeat
[144] Immunocore Holdings plc SEC Filing - Stock Titan
Immunocore (IMCR) upgraded to strong buy: Here's why - MSN
Immunocore (IMCR) Upgraded to Strong Buy: Here's Why - Yahoo Finance
SNY Stock Falls After Board Suddenly Makes Leadership Change - Finviz
Immunocore Holdings PLC Sponsored ADR $IMCR Stock Holdings Lifted by Candriam S.C.A. - MarketBeat
Immunocore Holdings PLC Sponsored ADR $IMCR Shares Sold by Principal Financial Group Inc. - MarketBeat
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
GSK Gets EU Approval for Expanded Use of Nucala in COPD - Finviz
HC Wainwright Weighs in on Immunocore FY2030 Earnings - Defense World
Bristol-Myers Stock Up as Q4 Earnings and Revenues Beat Estimates - Finviz
HC Wainwright Predicts Immunocore FY2030 Earnings - MarketBeat
NVO Q4 Earnings & Sales Beat Estimates, Stock Down on Poor 2026 View - Finviz
Acadia Expects Negative CHMP Opinion for Rett Syndrome Drug in EU - The Globe and Mail
NVO's CagriSema Outshines Semaglutide in Phase III Diabetes Study - Finviz
Immunocore Holdings (IMCR) is One of the Best Small Cap Stocks Ready to Explode in 2026 - Finviz
Immunocore announces resignation of head of research and development By Investing.com - Investing.com South Africa
Immunocore announces resignation of head of research and development - Investing.com
Immunocore announces executive leadership changes in R&D - Investing.com
TEVA's Q4 Earnings Beat, Branded Drugs Drive Revenue Growth - Finviz
Immunocore Holdings plc Share Price ADS Each Rep 1 Ord Share SPON - Hargreaves Lansdown
BHC's Late-Stage Liver Cirrhosis Studies Fail, Stock Down - The Globe and Mail
CORT Rises as Relacorilant Meets OS Endpoint in Ovarian Cancer Study - Finviz
MRNA & MRK's Personalized Cancer Therapy Delivers Strong 5-Year Data - sharewise.com
Immunocore (IMCR) Soars 5.9%: Is Further Upside Left in the Stock? - Yahoo Finance
FDA Grants Breakthrough Therapy Tag to LLY's Ovarian Cancer Candidate - Finviz
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
TVTX Stock Falls as FDA Extends Review Timeline for Filspari sNDA - Finviz
BEAM Outlines Key Strategic & Pipeline Goals for 2026, Stock Rises - Yahoo Finance
Immunocore Holdings Plc Adr (IMCR) 財務データ
収益
当期純利益
現金流量
EPS
Immunocore Holdings Plc Adr (IMCR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Jallal Bahija | CHIEF EXECUTIVE OFFICER |
Feb 18 '26 |
Sale |
32.35 |
11,474 |
371,184 |
12,343 |
| GOLL JOHN | SVP, FINANCE & CAO |
Feb 17 '26 |
Option Exercise |
0.00 |
1,351 |
0 |
1,351 |
| GOLL JOHN | SVP, FINANCE & CAO |
Feb 18 '26 |
Sale |
32.35 |
698 |
22,580 |
653 |
| St Leger Tina Amber | CHIEF HR OFFICER |
Feb 17 '26 |
Option Exercise |
0.00 |
2,119 |
0 |
2,119 |
| St Leger Tina Amber | CHIEF HR OFFICER |
Feb 18 '26 |
Sale |
32.35 |
1,000 |
32,350 |
1,119 |
| Berman David M | HEAD OF R&D |
Feb 17 '26 |
Option Exercise |
0.00 |
11,824 |
0 |
11,824 |
| Berman David M | HEAD OF R&D |
Feb 18 '26 |
Sale |
32.35 |
5,965 |
192,968 |
5,859 |
0.11%
6.00%
大文字化:
|
ボリューム (24 時間):